← Leaderboards

Robert Gross

University Of Pennsylvania

Google Scholar ↗PubMed ↗ORCID ↗

$16,941,227

Attributed

$23,413,590

Total exposure

14

Grants

7

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.2M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$23,413,590 · 14

By mechanism

R01$18,580,874 · 6

D43$1,704,215 · 1

P30$1,496,422 · 2

M01$1,043,396 · 4

K08$588,683 · 1

Top collaborators

Most similar at University Of Pennsylvania

Same institution · by research overlap

Rinad Sary Beidas$17,490,789
Ian Alexander Blair$30,276,296
Scott D Halpern$22,081,759
Brian Keith$1,921,761
Gregory K Brown$11,203,220

Others in their field

Top investigators on “Hiv Infections”

Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
Judith S. Currier · University Of California Los Angeles$466,447,923
Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678

Research focus

Hiv InfectionsClinical ResearchRandomizedHuman SubjectPersonsDesignAntiretroviral TherapyBaseBotswanaCountryMedication ComplianceSkillsLifeProtease InhibitorVirus LoadAids TherapyAntiaids AgentHuman Therapy EvaluationFutureSiteProblem SolvingSmoking CessationAffectSmoker

Grant awards (77)

International Core$235,857

P30 · FY2025 · AI · contact PI

Managed Problem Solving for ART Adherence and HIV Care Retention Delivered by Community Health Workers: A Stepped Wedge Hybrid Type II Effectiveness Implementation Trial$759,239

R01 · FY2024 · NR

Testing the Combination of Behavioral Activation and Problem Solving as a Novel Behavioral Smoking Cessation Intervention for Smokers with HIV in Botswana$582,347

R01 · FY2024 · DA · contact PI

International Core$245,613

P30 · FY2024 · AI · contact PI

Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV$215,558

R01 · FY2024 · CA

Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV$144,477

R01 · FY2024 · CA

Testing the Combination of Behavioral Activation and Problem Solving as a Novel Behavioral Smoking Cessation Intervention for Smokers with HIV in Botswana$143,970

R01 · FY2024 · DA · contact PI

Testing the Combination of Behavioral Activation and Problem Solving as a Novel Behavioral Smoking Cessation Intervention for Smokers with HIV in Botswana$647,960

R01 · FY2023 · DA · contact PI

Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV$606,133

R01 · FY2023 · CA

International Core$228,743

P30 · FY2023 · AI · contact PI

Testing the Combination of Behavioral Activation and Problem Solving as a Novel Behavioral Smoking Cessation Intervention for Smokers with HIV in Botswana$146,491

R01 · FY2023 · DA · contact PI

Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV$144,477

R01 · FY2023 · CA

Managed Problem Solving for ART Adherence and HIV Care Retention Delivered by Community Health Workers: A Stepped Wedge Hybrid Type II Effectiveness Implementation Trial$776,719

R01 · FY2022 · NR

Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV$616,693

R01 · FY2022 · CA

Testing the Combination of Behavioral Activation and Problem Solving as a Novel Behavioral Smoking Cessation Intervention for Smokers with HIV in Botswana$607,604

R01 · FY2022 · DA · contact PI

Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers$432,874

R01 · FY2022 · HL · contact PI

Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers$418,876

R01 · FY2022 · HL · contact PI

International Core$236,526

P30 · FY2022 · AI · contact PI

Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers$1,446,525

R01 · FY2021 · HL · contact PI

Managed Problem Solving for ART Adherence and HIV Care Retention Delivered by Community Health Workers: A Stepped Wedge Hybrid Type II Effectiveness Implementation Trial$794,441

R01 · FY2021 · NR

Testing the Combination of Behavioral Activation and Problem Solving as a Novel Behavioral Smoking Cessation Intervention for Smokers with HIV in Botswana$641,099

R01 · FY2021 · DA · contact PI

Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV$620,489

R01 · FY2021 · CA

Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers$536,730

R01 · FY2021 · HL · contact PI

International Core$184,292

P30 · FY2021 · AI · contact PI

Managed Problem Solving for ART Adherence and HIV Care Retention Delivered by Community Health Workers: A Stepped Wedge Hybrid Type II Effectiveness Implementation Trial$808,388

R01 · FY2020 · NR

Testing the Combination of Behavioral Activation and Problem Solving as a Novel Behavioral Smoking Cessation Intervention for Smokers with HIV in Botswana$640,866

R01 · FY2020 · DA · contact PI

Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers$541,423

R01 · FY2020 · HL · contact PI

Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV$408,139

R01 · FY2020 · CA

International Core$178,411

P30 · FY2020 · AI · contact PI

Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV$663,470

R01 · FY2019 · CA

International Core$186,980

P30 · FY2019 · AI · contact PI

HIV Research Training Program for Botswana$291,878

D43 · FY2018 · TW · contact PI

HIV Research Training Program for Botswana$302,206

D43 · FY2017 · TW · contact PI

HIV Research Training Program for Botswana$299,194

D43 · FY2016 · TW · contact PI

HIV Research Training Program for Botswana$163,296

D43 · FY2016 · TW · contact PI

HIV Research Training Program for Botswana$298,128

D43 · FY2015 · TW · contact PI

HIV Research Training Program for Botswana$49,948

D43 · FY2015 · TW · contact PI

HIV Research Training Program for Botswana$299,565

D43 · FY2014 · TW · contact PI

Pharmacogenetics and HIV treatment outcomes$368,182

R01 · FY2013 · MH · contact PI

Pharmacogenetics and HIV treatment outcomes$512,458

R01 · FY2012 · MH · contact PI

Pharmacogenetics and HIV treatment outcomes$619,615

R01 · FY2011 · MH · contact PI

Pharmacogenetics and HIV treatment outcomes$554,615

R01 · FY2010 · MH · contact PI

Pharmacogenetics and HIV treatment outcomes$44,333

R01 · FY2010 · MH · contact PI

Pharmacogenetics and HIV treatment outcomes$531,764

R01 · FY2009 · MH · contact PI

Managed problem solving: an HIV adherence trial$523,800

R01 · FY2009 · MH · contact PI

Managed problem solving: an HIV adherence trial$536,323

R01 · FY2008 · MH · contact PI

Managed problem solving: an HIV adherence trial$491,218

R01 · FY2007 · MH · contact PI

Managed problem solving: an HIV adherence trial$510,253

R01 · FY2006 · MH · contact PI

Managed problem solving: An HIV adherence trial$543,325

R01 · FY2005 · MH

ADHERENCE TO PROTEASE INHIBITORS IN HIV$149,353

K08 · FY2003 · MH

ADHERENCE TO PROTEASE INHIBITORS IN HIV$149,353

K08 · FY2002 · MH

ADHERENCE TO PROTEASE INHIBITORS IN HIV$124,146

M01 · FY2002 · RR

ACTG 398: AMPRENAVIR DUAL PROTEASE INHIBITOR REGIMEN$124,146

M01 · FY2002 · RR

ADHERENCE TO PROTEASE INHIBITORS IN HIV (LONG TERM)$124,146

M01 · FY2002 · RR

ACTG372 PHASE II STUDY OF PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$124,146

M01 · FY2002 · RR

ADHERENCE TO PROTEASE INHIBITORS IN HIV$149,353

K08 · FY2001 · MH

ADHERENCE TO PROTEASE INHIBITORS IN HIV (LONG TERM)$124,146

M01 · FY2001 · RR

ACTG 398: AMPRENAVIR DUAL PROTEASE INHIBITOR REGIMEN$124,146

M01 · FY2001 · RR

ACTG372 PHASE II STUDY OF PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$124,146

M01 · FY2001 · RR

ADHERENCE TO PROTEASE INHIBITORS IN HIV$124,146

M01 · FY2001 · RR

ADHERENCE TO PROTEASE INHIBITORS IN HIV$0

M01 · FY2001 · RR

ADHERENCE TO PROTEASE INHIBITORS IN HIV (LONG TERM)$0

M01 · FY2001 · RR

ACTG 398: AMPRENAVIR DUAL PROTEASE INHIBITOR REGIMEN$0

M01 · FY2001 · RR

ACTG372 PHASE II STUDY OF PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$0

M01 · FY2001 · RR

ADHERENCE TO PROTEASE INHIBITORS IN HIV$140,624

K08 · FY2000 · MH

ACTG372 PHASE II STUDY OF PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$25,114

M01 · FY2000 · RR

ADHERENCE TO PROTEASE INHIBITORS IN HIV$25,114

M01 · FY2000 · RR

ADHERENCE TO PROTEASE INHIBITORS IN HIV$0

M01 · FY2000 · RR

ADHERENCE TO PROTEASE INHIBITORS IN HIV (LONG TERM)$0

M01 · FY2000 · RR

ADHERENCE TO PROTEASE INHIBITORS IN HIV$0

M01 · FY2000 · RR

ACTG372 PHASE II STUDY OF PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$0

M01 · FY2000 · RR

ACTG 398: AMPRENAVIR DUAL PROTEASE INHIBITOR REGIMEN$0

M01 · FY2000 · RR

ADHERENCE TO PROTEASE INHIBITORS IN HIV (LONG TERM)$0

M01 · FY2000 · RR

ACTG 398: AMPRENAVIR DUAL PROTEASE INHIBITOR REGIMEN$0

M01 · FY2000 · RR

ACTG372 PHASE II STUDY OF PROLONGATION OF VIROLOGIC SUCCESS AND OPTIONS$0

M01 · FY2000 · RR

ACTG 398: AMPRENAVIR DUAL PROTEASE INHIBITOR REGIMEN$0

M01 · FY2000 · RR

ADHERENCE TO PROTEASE INHIBITORS IN HIV (LONG TERM)$0

M01 · FY2000 · RR